Chen, Julius L.
Chernew, Michael E.
Fendrick, A. Mark
Thompson, Joseph W.
Rose, Sherri
Article History
Received: 14 November 2018
Revised: 4 June 2019
Accepted: 8 August 2019
First Online: 16 September 2019
Compliance with Ethical Standards
:
: Dr. Chernew reports having equity in Archway Health, V-BID Health, Virta Health, and Paladin Healthcare Capital. He reports having consulted for the American Hospital Association, Anthem Health Insurance, Janssen Pharmaceuticals, Madalena Consulting, Merck & Company, Milliman, Navigant, Pfizer, PhRMA, Precision Health Economics, State of North Carolina, Takeda Pharmaceuticals, University of Michigan, White & Case, Amgen, J&J, Sanofi, University of Maine, McKinsey & Company, and John Freedman Healthcare. He has received research funding from the Laura and John Arnold Foundation, NIH/NIA, NBER/AHRQ, CMS via Abt Associates, MITRE/CMS, Altarum/RWJK, Peterson Center on Health Care, and The Commonwealth Fund. Dr. Fendrick reports having consulted for AbbVie, Amgen, Centivo, Community Oncology Association, Department of Defense, EmblemHealth, Exact Sciences, Freedman Health, Health at Scale Technologies, Health Management Associates, Lilly, MedZed, Penguin Pay, Risalto, Sempre Health, State of Minnesota, Wellth, and Zansors. He has received research funding from AHRQ, Boehringer-Ingelheim, Gary and Mary West Health Policy Center, Laura and John Arnold Foundation, National Pharmaceutical Council, PCORI, PhRMA, RWJ Foundation, and State of Michigan/CMS. All other authors report no relationships or potential conflicts of interest.
Free to read: This content has been made available to all.